Background Image
Menu

Latest News

Oxford BioTherapeutics announces collaboration with Agenus

26 May 2022

Oxford BioTherapeutics announces collaboration with Agenus

Oxford BioTherapeutics announces collaboration with Agenus to support the clinical development of OBT’s antibody drug conjugate OBT076 in combination with Agenus’ CPI Balstilimab … • New deal enables Oxford BioTherapeutics (OBT) to evaluate OBT076 with a checkpoint...

CARB-X receives additional $370m from U.S. Government and Wellcome

26 May 2022

CARB-X receives additional $370m from U.S. Government and Wellcome

Funding will enable continued investment in innovative projects to tackle the growing global threat posed by AMR … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, welcomes the news that CARB-X (Combating Antibiotic...

Blueberry Therapeutics provides regulatory update on Phase 2b trial

25 May 2022

Blueberry Therapeutics provides regulatory update on Phase 2b trial

Alderley Park, 24 May 2022 – Blueberry Therapeutics has reported significant progress in its Phase 2b European trial of BB2603 in onychomycosis (BBTAF202). The COVID-19 pandemic led to operational challenges in all 3 participating countries (Germany, Poland and Czech...

Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme

17 May 2022

Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme

MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022 … Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval from the UK Medicines and Healthcare...

Maxwellia appoints Ian Adamson as Strategic Advisor

16 May 2022

Maxwellia appoints Ian Adamson as Strategic Advisor

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a...

Catapult Ventures records 3.3x return from exit of Panthera Biopartners

28 April 2022

Catapult Ventures records 3.3x return from exit of Panthera Biopartners

28 April 2022 - Manchester, UK. The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd. The exit comes as part of a £10m further funding package for Panthera from Business...

Medicine switching expert Maxwellia continues to drive shift to self-care with two more pharmacy products in the launch pipeline

26 April 2022

Medicine switching expert Maxwellia continues to drive shift to self-care with two more pharmacy products in the launch pipeline

MANCHESTER, England, April 22, 2022 /PRNewswire/ -- Following the reclassification of the daily progestogen-only pill earlier this year, Maxwellia made history by launching Lovima® (desogestrel 75mcg) one of the first oral contraceptive brands to be available in pharmacy. It...

Oxford BioTherapeutics grants third exclusive license to Boehringer Ingelheim

13 April 2022

Oxford BioTherapeutics grants third exclusive license to Boehringer Ingelheim

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target … OXFORD, England and SAN JOSE, Calif., April 13, 2022 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a clinical...

OBT to present preliminary clinical data from ongoing Expansion Phase I Trial

11 April 2022

OBT to present preliminary clinical data from ongoing Expansion Phase I Trial

• Initial data from the Phase 1 dose escalation part of the OBT076 trial in adult patients with advanced solid tumors indicated that OBT076 had a favorable tolerability profile; recommended dose was defined at 3.0 mg/kg … • OBT076 showed preliminary signs of clinical activity as...

Proveca announces agreement with Biopas Laboratories

7 April 2022

Proveca announces agreement with Biopas Laboratories

Proveca Ltd is excited to announce a significant agreement outside Europe with Biopas Laboratories based in Colombia. Biopas will commercialise and distribute Sialanar® exclusively throughout Spanish speaking territories in South America. Under the terms of the agreement...